Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study

What Was Tested

The paper reports a study of Octreotide and Somatostatin, published as a clinical trial.

Patients received 6.9-7.3 GBq (standard injected radioactivity) of [177Lu]Lu-DOTATOC followed by 3.3-4.9 GBq (2 GBq/m2 × body surface area) of [177Lu]Lu-DOTA-JR11 at an interval of 10 ± 1 wk.

In total, 1 [177Lu]Lu-DOTATOC and 2-3 [177Lu]Lu-DOTA-JR11 treatment cycles were performed.

Who Took Part

According to the abstract, 6 patients were involved.

By PubMed's age tags, the people studied were middle-aged adults, both men and women.

Methods: In this prospective, single-center, open-label phase 0 study (NCT04997317), 6 consecutive patients were included: 3 men and 3 women (mean age, 63.5 y).

How the Study Was Run

The design is described as open-label.

Everyone knew when Octreotide was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

What Was Measured

Topics PubMed links to this paper include Lymphopenia, Meningeal Neoplasms, Meningioma, Neuroendocrine Tumors, Octreotide, Organometallic Compounds and Radioisotopes.

The authors tagged it with the keywords DOTA-JR11, DOTATOC and peptide receptor radionuclide therapy.

What This Means in Plain Language

The paper is an open-label study of Octreotide and Somatostatin in 6 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2024 (Journal of nuclear medicine : official publication, Society of Nuclear Medicine), a journal based in United States.

More context: the Octreotide compound page and the Somatostatin compound page, all human trials.